Department of Infectious Disease, Faculty of Medical Sciences, Sari Branch, Islamic Azad University, Sari, Iran.
Department of Hematology and Blood Banking, School of Medicine, Tarbiat Modares University, Tehran, Iran.
Eur J Pharmacol. 2021 Oct 5;908:174380. doi: 10.1016/j.ejphar.2021.174380. Epub 2021 Jul 22.
The aim of the current study was to perform a meta-analysis of randomized clinical trials regarding the effect of resveratrol in decreasing the levels of inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-α in a combination of inflammatory diseases. Literature search was carried out in Scopus, ISI web of science, Medline, and Cochrane Library databases by up to September 2020. The pooled effect size was determined through measuring the weighted mean differences (WMD) and their corresponding 95% confidence intervals (CI) for the difference between the resveratrol-receiving and control groups. Finally, 33 publications, including 3 studies on IL-1, 26 studies on IL-6, 4 studies on IL-8, and 21 studies on TNF-α met our final inclusion criteria and included in the quantitative analysis. Analysis in the overall population showed a significant effect of resveratrol consumption in reducing serum TNF-α levels (WMD = -0.66 pg/ml, 95% CI = -1.05 to -0.27, P = 0.001). A significant reduction of IL-6 concentration was observed only in the patients receiving ≥500 mg/day dose of resveratrol (WMD = -1.89 pg/ml, 95% CI = -3.73 to -0.05, P = 0.04) with inter-study heterogeneity (I = 94.4%, P < 0.001). Nonetheless, no significant alteration was observed in IL-1 (WMD = -0.14 pg/ml, 95% CI = -0.31 to 0.03, P = 0.10) and IL-8 (WMD = 0.18 pg/ml, 95% CI = -1.04 to 1.40, P = 0.73) levels following resveratrol consumption. Based on the present findings, resveratrol is able to decrease TNF-α and IL-6 (in ≥500 mg/day dose) levels but not IL-1 and IL-8 levels.
本研究的目的是对随机临床试验进行荟萃分析，评估白藜芦醇在降低炎症性疾病中炎症细胞因子（包括白细胞介素（IL）-1、IL-6、IL-8 和肿瘤坏死因子（TNF）-α）水平方面的效果。文献检索在 Scopus、ISI web of science、Medline 和 Cochrane Library 数据库中进行，截至 2020 年 9 月。通过测量白藜芦醇组和对照组之间的加权均数差值（WMD）及其相应的 95%置信区间（CI）来确定汇总效应大小。最终，有 33 项研究符合我们的最终纳入标准，包括 3 项关于 IL-1 的研究、26 项关于 IL-6 的研究、4 项关于 IL-8 的研究和 21 项关于 TNF-α 的研究，并且被纳入定量分析。总体人群分析显示，白藜芦醇的摄入对降低血清 TNF-α水平有显著效果（WMD=-0.66 pg/ml，95%CI=-1.05 至-0.27，P=0.001）。仅在接受白藜芦醇≥500mg/天剂量的患者中观察到 IL-6 浓度的显著降低（WMD=-1.89 pg/ml，95%CI=-3.73 至-0.05，P=0.04），且研究间存在异质性（I=94.4%，P<0.001）。然而，白藜芦醇摄入后，IL-1（WMD=-0.14 pg/ml，95%CI=-0.31 至 0.03，P=0.10）和 IL-8（WMD=0.18 pg/ml，95%CI=-1.04 至 1.40，P=0.73）水平无显著变化。基于目前的研究结果，白藜芦醇能够降低 TNF-α和 IL-6（在≥500mg/天剂量下）水平，但不能降低 IL-1 和 IL-8 水平。
